Calliditas announces additions to the management team

Rhea-AI Summary

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) has announced the addition of a new member to its management team, Head of Technical Operations Lars Stubberud, and the appointment of Brian Gorman as its new Group General Counsel, effective 1 January 2024.

STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the company has added a new member to its management team, Head of Technical Operations Lars Stubberud. Additionally, the company is welcoming Brian Gorman as its new Group General Counsel. These changes will take effect on 1 January 2024.

Brian Gorman is an accomplished legal and business executive with more than 20 years of experience advising corporate boards and executive management teams of life science companies. He joins Calliditas after having served most recently as Executive Vice President, Corporate Development & General Counsel at Opiant Pharmaceuticals, which was acquired by Indivior PLC.  Prior to Opiant, Brian held senior legal leadership roles at Endo Pharmaceuticals, AstraZeneca, and Wyeth Pharmaceuticals (now Pfizer). He began his career at the international law firm, Cleary Gottlieb Steen & Hamilton. He is a graduate of Gettysburg College and the Villanova University School of Law. Brian Gorman is replacing Jonathan Schur, who has decided to retire.

"Jonathan has been instrumental in building up the US operations for Calliditas in every way and he will be sorely missed by all.  We wish him the very best.  We welcome Brian to the team and look forward to working with him as we embark on the next chapter of our journey," said Renée Aguiar-Lucander, CEO Calliditas.

Lars Stubberud has more than 30 years' experience in the pharmaceutical industry within the broader CMC area, including Formulation Sciences, Product Development, Technology Transfer/Technical Stewardship as well as Regulatory Affairs- CMC and Quality Assurance. Prior to joining Calliditas in 2020, Lars has held various positions, including leadership roles, at Nyomed AS, AstraZeneca, as well as Cubist Pharmaceuticals GmbH, Biogen International GmbH and Alexion Pharma GmbH. Lars has a Master of Science (candidatus pharmaciae) and PhD in Pharmaceutical Science from the University of Oslo, Norway.

CONTACT:

For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com

The information was sent for publication, through the agency of the contact persons set out above, on 1 December, 2023 at 09:00 a.m. CET.

The following files are available for download:

https://mb.cision.com/Main/16574/3886166/2467390.pdf

Management Team PR_ENG

 

View original content:https://www.prnewswire.com/news-releases/calliditas-announces-additions-to-the-management-team-302003062.html

SOURCE Calliditas Therapeutics

FAQ

Who is the new Head of Technical Operations at Calliditas Therapeutics AB?

Lars Stubberud is the new Head of Technical Operations at Calliditas Therapeutics AB.

Who is the new Group General Counsel at Calliditas Therapeutics AB?

Brian Gorman is the new Group General Counsel at Calliditas Therapeutics AB.

What is the ticker symbol for Calliditas Therapeutics AB?

The ticker symbol for Calliditas Therapeutics AB is CALT.

When will the new management team members take effect?

The new management team members, Lars Stubberud and Brian Gorman, will take effect on 1 January 2024.

What is the educational background of Lars Stubberud?

Lars Stubberud has a Master of Science (candidatus pharmaciae) and a PhD in Pharmaceutical Science from the University of Oslo, Norway.

What is the professional background of Brian Gorman?

Brian Gorman is an accomplished legal and business executive with more than 20 years of experience advising corporate boards and executive management teams of life science companies.